Peginterferon alpha-2b + ribavirin 併用療法の効果判定における COBAS AmpliPre/COBAS TaqMan HCV test の有用性 Clinical utility of COBAS AmpliPre/COBAS TaqMan HCV test for evaluating the efficacy of peginterferon plus ribavirin therapy

この論文にアクセスする

この論文をさがす

著者

抄録

We evaluated the performance characteristics of Amplicor HCV v2.0 (Amplicor HCV) and COBAS AmpliPre/COBAS TaqMan HCV test (TaqMan HCV) for predicting sustained virological response (SVR) at 4, 8, and 12 weeks in patients treated with peginterferon plus ribavirin therapy. In genotype 1, the percentage of patients having SVR with undetectable HCV RNA by TaqMan HCV at 8 and 12 weeks is higher than that by Amplicor HCV (90.0% and 72.2% vs 84.6% and 60.0%). However, in genotype 2, there was no difference between Amplicor HCV and TaqMan HCV. We believe TaqMan HCV is useful for determining the duration of treatment with peginterferon plus ribavirin therapy, especially in genotype 1.<br>

収録刊行物

  • 肝臓 = ACTA HEPATOLOGICA JAPONICA  

    肝臓 = ACTA HEPATOLOGICA JAPONICA 49(4), 171-173, 2008-04-25 

    The Japan Society of Hepatology

参考文献:  3件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021938905
  • NII書誌ID(NCID)
    AN00047770
  • 本文言語コード
    JPN
  • 資料種別
    SHO
  • ISSN
    04514203
  • NDL 記事登録ID
    9477674
  • NDL 雑誌分類
    ZS21(科学技術--医学--内科学)
  • NDL 請求記号
    Z19-130
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ